Etibo

✅ Targets cancer cells
✅ Inhibits tumor growth
✅ Treats breast cancer
✅ Blocks HER2 receptors
✅ Improves survival rates

Etibo contains Lapatinib.

Product Overview

Etibo is a medication containing the active ingredient Lapatinib. It is available in tablet form and is primarily prescribed for the treatment of certain types of breast cancer and other solid tumors. Lapatinib is a tyrosine kinase inhibitor that works by blocking the action of specific proteins involved in the growth and spread of cancer cells. Etibo is often used in combination with other cancer treatments, such as chemotherapy or hormonal therapy, as part of a comprehensive treatment plan.

Uses

Etibo is indicated for the treatment of HER2-positive breast cancer, which is a type of breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) protein. It is also used in combination with capecitabine for the treatment of advanced or metastatic breast cancer that has progressed despite prior therapy. Additionally, Etibo may be prescribed for the treatment of other solid tumors, including certain types of gastrointestinal and lung cancers, in patients who have failed prior therapy.

How to Use

Etibo tablets should be taken orally with a glass of water, either with food or on an empty stomach, as directed by your healthcare provider. It is essential to swallow the tablets whole and not crush, chew, or break them. The dosage and duration of treatment with Etibo will vary depending on the specific type and stage of cancer being treated, as well as individual patient factors. Follow your doctor’s instructions carefully and do not adjust your dose without consulting them.

How it Works

Lapatinib, the active ingredient in Etibo, is a reversible inhibitor of both epidermal growth factor receptor (EGFR) and HER2 tyrosine kinases. These proteins play a crucial role in the signaling pathways that regulate cell growth and proliferation. By blocking the activity of EGFR and HER2, Lapatinib interferes with the growth and survival of cancer cells, ultimately leading to their death. This mechanism helps slow down or stop the progression of cancer and may shrink tumors in some patients.

Dosage and Administration

The recommended dosage of Etibo for the treatment of breast cancer is typically 1,250 mg once daily, taken continuously until disease progression or unacceptable toxicity occurs. When used in combination with capecitabine, the recommended dosage is 1,250 mg once daily on days 1-21 of a 21-day cycle, repeated until disease progression or unacceptable toxicity. Dosage adjustments may be necessary based on individual patient factors, such as liver function and concomitant medications.

Benefits

The primary benefit of Etibo is its ability to effectively target and inhibit the activity of EGFR and HER2 proteins, which are overexpressed in certain types of cancer cells. By blocking these proteins, Etibo helps slow down or halt the growth and spread of cancer, improving patient outcomes and prolonging survival. In addition to its direct anticancer effects, Etibo may also enhance the efficacy of other cancer treatments when used in combination therapy, leading to better overall disease control.

Common Side Effects

Common side effects associated with Etibo may include diarrhea, rash, nausea, vomiting, fatigue, and headache. These side effects are usually mild to moderate in severity and may improve with continued use of the medication. However, some patients may experience more severe side effects, such as liver toxicity or heart problems, which require prompt medical attention. It is essential to report any new or worsening symptoms to your healthcare provider for evaluation and management.

Warnings

Etibo may cause severe or life-threatening side effects, including liver toxicity, heart failure, and lung problems. It is important to undergo regular monitoring of liver function, cardiac function, and pulmonary function while taking Etibo. Patients should also avoid consuming grapefruit or grapefruit juice during treatment with Etibo, as it may increase the risk of side effects. Additionally, women of childbearing age should use effective contraception during treatment, as Etibo may harm the unborn baby.

Storage Information

Store Etibo tablets at room temperature away from moisture, heat, and light. Keep the medication out of reach of children and pets. Do not use Etibo beyond the expiration date printed on the packaging. Proper storage ensures the stability and effectiveness of the medication throughout its shelf life.

Disclaimer:

Our sole intention is to ensure that its consumers get information that is expert-reviewed, accurate, and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions, or warnings or alerts. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

Additional Information

Strength

250 mg

Quantity

30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s

Reviews

There are no reviews yet.

Be the first to review “Etibo”